Symbols / IKT Stock $1.89 -0.26% Inhibikase Therapeutics, Inc.
IKT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Ratings
Current target
$1.89
Low
$3.00
High
$8.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | init | Ladenburg Thalmann | — → Buy | $4 |
| 2026-01-21 | init | B of A Securities | — → Buy | $6 |
| 2025-12-17 | init | Freedom Broker | — → Buy | $3 |
| 2025-12-11 | init | Cantor Fitzgerald | — → Overweight | $4 |
| 2025-03-28 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-12 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-08 | init | Jefferies | — → Buy | $8 |
| 2024-10-14 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-21 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-03-05 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2023-06-30 | main | HC Wainwright & Co. | Buy → Buy | $27 |
News
RSS: Latest IKT news- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat Fri, 01 May 2026 08
- [DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan hu, 30 Apr 2026 20
- $IKT stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 08
- A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st Fri, 27 Feb 2026 08
- Inhibikase Therapeutics Announces Enrollment of First - GlobeNewswire ue, 07 Apr 2026 12
- IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade Mon, 23 Feb 2026 08
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance hu, 20 Nov 2025 08
- IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Wed, 22 Apr 2026 07
- Insider Purchase: 10% owner at $IKT Buys 2,068,965 Shares - Quiver Quantitative Mon, 24 Nov 2025 08
- While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st ue, 16 Dec 2025 08
- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat Mon, 06 Apr 2026 07
- Five new Inhibikase hires get stock options priced at $1.68 - Stock Titan Fri, 03 Apr 2026 07
- Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewswire hu, 20 Nov 2025 08
- First patient enters global late-stage trial for PAH drug IKT-001 - Stock Titan ue, 07 Apr 2026 07
- Inhibikase opens global PAH Phase 3 trial after 20-country filings - Stock Titan hu, 26 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
53.35
+86.60%
|
28.59
+42.31%
|
20.09
+10.82%
|
18.13
|
| Research And Development |
|
29.79
+73.11%
|
17.21
+26.38%
|
13.62
+13.16%
|
12.03
|
| Selling General And Administration |
|
23.56
+107.01%
|
11.38
+69.02%
|
6.73
+8.28%
|
6.22
|
| Other Operating Expenses |
|
—
|
—
|
-0.26
-111.03%
|
-0.12
|
| Total Expenses |
|
53.35
+86.60%
|
28.59
+42.31%
|
20.09
+10.82%
|
18.13
|
| Operating Income |
|
-53.35
-86.60%
|
-28.59
-42.31%
|
-20.09
-10.82%
|
-18.13
|
| Total Operating Income As Reported |
|
-51.97
-81.80%
|
-28.59
-42.31%
|
-20.09
-10.82%
|
-18.13
|
| EBITDA |
|
-53.29
-86.56%
|
-28.56
-43.44%
|
-19.91
-9.88%
|
-18.12
|
| Normalized EBITDA |
|
-54.66
-91.37%
|
-28.56
-43.44%
|
-19.91
-9.88%
|
-18.12
|
| Reconciled Depreciation |
|
0.06
+130.28%
|
0.03
-85.19%
|
0.18
+2538.67%
|
0.01
|
| EBIT |
|
-53.35
-86.60%
|
-28.59
-42.31%
|
-20.09
-10.82%
|
-18.13
|
| Total Unusual Items |
|
1.37
|
0.00
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
1.37
|
0.00
|
—
|
—
|
| Special Income Charges |
|
1.37
|
0.00
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
-1.37
|
0.00
|
—
|
—
|
| Net Income |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Pretax Income |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Net Non Operating Interest Income Expense |
|
3.72
+247.47%
|
1.07
+0.78%
|
1.06
+1324.94%
|
0.07
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
3.72
+247.47%
|
1.07
+0.78%
|
1.06
+1324.94%
|
0.07
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
3.72
+247.47%
|
1.07
+0.78%
|
1.06
+1324.94%
|
0.07
|
| Interest Income |
|
3.72
+247.47%
|
1.07
+0.78%
|
1.06
+1324.94%
|
0.07
|
| Other Income Expense |
|
1.37
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Net Income From Continuing And Discontinued Operation |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Net Income Continuous Operations |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Normalized Income |
|
-49.63
-80.35%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Net Income Common Stockholders |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Diluted EPS |
|
—
|
-1.16
+63.29%
|
-3.16
+26.17%
|
-4.28
|
| Basic EPS |
|
—
|
-1.16
+63.29%
|
-3.16
+26.17%
|
-4.28
|
| Basic Average Shares |
|
—
|
23.71
+293.35%
|
6.03
+42.74%
|
4.22
|
| Diluted Average Shares |
|
—
|
23.71
+293.35%
|
6.03
+42.74%
|
4.22
|
| Diluted NI Availto Com Stockholders |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
181.20
+83.78%
|
98.60
+579.69%
|
14.51
-41.83%
|
24.94
|
| Current Assets |
|
180.11
+82.94%
|
98.45
+592.78%
|
14.21
-41.69%
|
24.37
|
| Cash Cash Equivalents And Short Term Investments |
|
178.76
+83.27%
|
97.54
+636.06%
|
13.25
-42.51%
|
23.05
|
| Cash And Cash Equivalents |
|
139.22
+146.45%
|
56.49
+516.36%
|
9.17
+27.50%
|
7.19
|
| Cash Financial |
|
—
|
—
|
—
|
7.19
|
| Other Short Term Investments |
|
39.54
-3.68%
|
41.05
+904.51%
|
4.09
-74.23%
|
15.86
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Accounts Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Prepaid Assets |
|
1.00
+1132.34%
|
0.08
-63.01%
|
0.22
-80.33%
|
1.12
|
| Other Current Assets |
|
0.34
-58.45%
|
0.83
+11.81%
|
0.74
+352.23%
|
0.16
|
| Total Non Current Assets |
|
1.10
+637.27%
|
0.15
-49.75%
|
0.30
-47.70%
|
0.57
|
| Net PPE |
|
0.00
-100.00%
|
0.15
-49.75%
|
0.30
-47.70%
|
0.57
|
| Gross PPE |
|
0.00
-100.00%
|
0.21
-37.05%
|
0.33
-42.99%
|
0.57
|
| Accumulated Depreciation |
|
0.00
+100.00%
|
-0.06
-86.27%
|
-0.03
-352.97%
|
-0.01
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.00
-100.00%
|
0.10
-54.35%
|
0.22
-32.38%
|
0.33
|
| Machinery Furniture Equipment |
|
0.00
-100.00%
|
0.10
+0.00%
|
0.10
+15.89%
|
0.09
|
| Other Properties |
|
—
|
—
|
0.02
-89.01%
|
0.15
|
| Non Current Prepaid Assets |
|
1.00
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
0.10
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
8.30
+122.33%
|
3.73
+5.80%
|
3.53
-9.54%
|
3.90
|
| Current Liabilities |
|
8.30
+122.33%
|
3.73
+8.58%
|
3.44
-6.95%
|
3.70
|
| Payables And Accrued Expenses |
|
1.98
-24.66%
|
2.62
-1.10%
|
2.65
-14.13%
|
3.09
|
| Payables |
|
1.16
+22.80%
|
0.94
-8.32%
|
1.03
-10.65%
|
1.15
|
| Accounts Payable |
|
1.16
+22.80%
|
0.94
+45.81%
|
0.65
-43.82%
|
1.15
|
| Other Payable |
|
—
|
—
|
0.38
|
—
|
| Current Accrued Expenses |
|
0.82
-51.30%
|
1.68
+3.46%
|
1.62
-16.20%
|
1.94
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.26
+226.50%
|
1.00
+57.26%
|
0.64
+38.14%
|
0.46
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.11
-26.37%
|
0.15
+2.92%
|
0.15
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.11
-26.37%
|
0.15
+2.92%
|
0.15
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
3.06
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.09
-56.13%
|
0.21
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.09
-56.13%
|
0.21
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.09
-56.13%
|
0.21
|
| Stockholders Equity |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Common Stock Equity |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Capital Stock |
|
0.13
+89.86%
|
0.07
+1021.27%
|
0.01
+46.45%
|
0.00
|
| Common Stock |
|
0.13
+89.86%
|
0.07
+1021.27%
|
0.01
+46.45%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
131.69
+89.86%
|
69.36
+1021.23%
|
6.19
+47.13%
|
4.20
|
| Ordinary Shares Number |
|
131.69
+89.86%
|
69.36
+1021.23%
|
6.19
+47.13%
|
4.20
|
| Additional Paid In Capital |
|
315.43
+66.67%
|
189.25
+143.03%
|
77.87
+13.19%
|
68.80
|
| Retained Earnings |
|
-142.68
-51.11%
|
-94.42
-41.14%
|
-66.90
-39.75%
|
-47.87
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
+158.53%
|
-0.04
-4347.21%
|
0.00
-99.16%
|
0.10
|
| Other Equity Adjustments |
|
0.02
+158.53%
|
-0.04
-4347.21%
|
0.00
-99.16%
|
0.10
|
| Total Equity Gross Minority Interest |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Total Capitalization |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Working Capital |
|
171.81
+81.39%
|
94.72
+779.26%
|
10.77
-47.90%
|
20.68
|
| Invested Capital |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Total Debt |
|
0.00
-100.00%
|
0.11
-53.99%
|
0.24
-31.62%
|
0.35
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.11
-53.99%
|
0.24
-31.62%
|
0.35
|
| Net Tangible Assets |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Tangible Book Value |
|
172.90
+82.26%
|
94.87
+764.16%
|
10.98
-47.81%
|
21.04
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-27.79
-45.11%
|
-19.15
-5.88%
|
-18.09
-4.23%
|
-17.35
|
| Cash Flow From Continuing Operating Activities |
|
-27.79
-45.11%
|
-19.15
-5.88%
|
-18.09
-4.23%
|
-17.35
|
| Net Income From Continuing Operations |
|
-48.26
-75.36%
|
-27.52
-44.62%
|
-19.03
-5.40%
|
-18.05
|
| Depreciation Amortization Depletion |
|
0.06
+130.28%
|
0.03
-85.19%
|
0.18
+2538.67%
|
0.01
|
| Depreciation |
|
0.06
+130.28%
|
0.03
-85.19%
|
0.18
+2538.67%
|
0.01
|
| Depreciation And Amortization |
|
0.06
+130.28%
|
0.03
-85.19%
|
0.18
+2538.67%
|
0.01
|
| Other Non Cash Items |
|
-1.37
|
—
|
0.03
-52.93%
|
0.07
|
| Stock Based Compensation |
|
15.31
+88.07%
|
8.14
+1527.64%
|
0.50
+9.17%
|
0.46
|
| Asset Impairment Charge |
|
7.36
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.06
-72.71%
|
0.20
-12.71%
|
0.23
+37.14%
|
0.17
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.04
-43.24%
|
0.07
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
0.04
-43.24%
|
0.07
|
| Change In Prepaid Assets |
|
-1.39
-190.36%
|
-0.48
-156.74%
|
0.84
+156.32%
|
0.33
|
| Change In Payables And Accrued Expense |
|
1.55
+123.76%
|
0.69
+207.62%
|
-0.64
-151.20%
|
-0.26
|
| Change In Accrued Expense |
|
1.40
+233.57%
|
0.42
+403.34%
|
-0.14
+56.36%
|
-0.32
|
| Change In Payable |
|
0.15
-45.98%
|
0.27
+153.88%
|
-0.50
-921.58%
|
0.06
|
| Change In Account Payable |
|
0.15
-45.98%
|
0.27
+153.88%
|
-0.50
-921.58%
|
0.06
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
0.04
|
| Change In Other Current Assets |
|
0.01
-94.77%
|
0.12
+13.51%
|
0.11
+179.64%
|
0.04
|
| Change In Other Current Liabilities |
|
-0.11
+14.79%
|
-0.13
-16.78%
|
-0.11
-1026.56%
|
-0.01
|
| Investing Cash Flow |
|
2.05
+105.55%
|
-37.00
-417.45%
|
11.66
+172.83%
|
-16.01
|
| Cash Flow From Continuing Investing Activities |
|
2.05
+105.55%
|
-37.00
-417.45%
|
11.66
+172.83%
|
-16.01
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
+100.00%
|
-0.01
+94.15%
|
-0.24
|
| Purchase Of PPE |
|
-0.01
|
0.00
+100.00%
|
-0.01
+94.15%
|
-0.24
|
| Capital Expenditure |
|
-0.45
|
—
|
-0.01
+94.15%
|
-0.24
|
| Net Investment Purchase And Sale |
|
2.51
+106.77%
|
-37.00
-417.06%
|
11.67
+174.04%
|
-15.76
|
| Purchase Of Investment |
|
-39.09
+35.33%
|
-60.46
-105.45%
|
-29.43
-41.98%
|
-20.73
|
| Sale Of Investment |
|
41.60
+77.39%
|
23.45
-42.94%
|
41.10
+728.07%
|
4.96
|
| Net Intangibles Purchase And Sale |
|
-0.44
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.44
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
108.46
+4.82%
|
103.48
+1131.14%
|
8.41
+4204.63%
|
-0.20
|
| Cash Flow From Continuing Financing Activities |
|
108.46
+4.82%
|
103.48
+1131.14%
|
8.41
+4204.63%
|
-0.20
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Net Common Stock Issuance |
|
107.62
+4.00%
|
103.48
+1111.18%
|
8.54
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.85
|
0.00
|
0.00
-100.00%
|
0.04
|
| Net Other Financing Charges |
|
—
|
—
|
-0.14
|
—
|
| Changes In Cash |
|
82.73
+74.81%
|
47.33
+2294.25%
|
1.98
+105.89%
|
-33.56
|
| Beginning Cash Position |
|
56.49
+516.36%
|
9.17
+27.50%
|
7.19
-82.36%
|
40.75
|
| End Cash Position |
|
139.22
+146.45%
|
56.49
+516.36%
|
9.17
+27.50%
|
7.19
|
| Free Cash Flow |
|
-28.24
-47.47%
|
-19.15
-5.79%
|
-18.10
-2.87%
|
-17.59
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Amortization Of Securities |
|
-0.94
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
107.62
+4.00%
|
103.48
+1111.18%
|
8.54
|
0.00
|
| Issuance Of Capital Stock |
|
107.62
+4.00%
|
103.48
+1111.18%
|
8.54
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-02-24 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 8-K2025-12-19 View
- 42025-11-24 View
- 8-K2025-11-21 View
- 8-K2025-11-20 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 42025-08-28 View
- 10-Q2025-08-14 View
- 8-K2025-08-14 View
- 42025-07-02 View
- 42025-07-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|